

The New Medicines Group's role in advising AWMSG

Dr James Coulson BSc LL.M MD FRCP ERT
Chair, New Medicines Group

All Wales Medicines Strategy Group
Grŵp Strategaeth Meddyginiaethau Cymru Gyfan



Thank You!

- Dr Saad Al-Ismael Chair of the New Medicines Group 2014 to June 2018
 - Chair of the Cancer Commissioning Group- ABM University Health Board,
 - Chair of the Thrombosis and Anticoagulation Committee at ABM University Health Board.
 - MDT Lead Consultant Haematologist in ABM University Health Board
 - Medical Director and lead cancer clinician for South West Wales cancer Network (2000-2011).





The New Medicines Group's role in advising AWMSG

- The role of New Medicines Group in the Health Technology Appraisal process
- How New Medicines Group operates
- Submissions to New Medicines Group: five year trends
- Future challenges



New Medicines Group role within Health Technology Appraisal



New Medicines Group (NMG)

NMG evaluates:

1. Written evidence from the applicant company,
2. AWMSG Secretariat Assessment Report (NMG led & AWTTTC led)
3. Views from clinical experts in the field
4. Views of relevant patients/carers/patient organisations.

NMG considers:

1. Clinical effectiveness
2. Cost-effectiveness


NMG makes preliminary recommendation to AWMSG




**10 meetings
a year**

NMG Membership


Voting Members (14)	Non-voting Members
<p>1 Chair 3 Pharmacists 3 Doctors 1 Professional eligible to prescribe 1 Nurse 1 Public Health Wales representative 1 Health Economist 1 ABPI Cymru Wales representative 1 Lay member 1 Welsh Health Specialised Services Committee representative</p>	<ul style="list-style-type: none">• Welsh Government (Chief Pharmaceutical officer)• AWMSG Chair (or nominee)• AWTTC Representative• Medicines & Therapeutics Committees• Health Economist
<p>AWTTC Secretariat</p>	




Total number of submissions to NMG: 5 year trend




Types of submission to NMG: 5 year trend




Full submissions to NMG by therapeutic class (BNF chapter)



Limited submissions to NMG by therapeutic class (BNF chapter)



Percentage of medicines recommended* by NMG and AWMSG



*Includes “recommended with restrictions”

p = 0.16

Future challenges

Factor	Analysis	Deduction
Number of medicines to review at each meeting	Declining total number of submissions and increasing proportion of limited	<ul style="list-style-type: none">• Increasing time for training and other quality improvement activities• Virtual meetings
Classes of medicines	Increasing variety of therapeutic area	Increasing requirement for diverse clinical expert & patients groups
Recommendations to AWMSG	More details of decision requested by AWMSG – trial of decision table	Measure of effects required

Thank you

All Wales Medicines Strategy Group
Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

